News
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July ANTHEM Phase 2b trial data of icotrokinra in ulcerative colitis scheduled for an oral presentation at the 33rd United European Gastroenterology Week (UEGW) on October 7th
The company reported $39.7 billion in loan originations for the quarter, up from $32.4 billion in the previous quarter.
Martin Marietta Materials posted a 12% rise in second-quarter profit on Thursday, aided by stronger pricing and ...
LAFAYETTE, LA / ACCESS Newswire / August 6, 2025 / Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), an ...
Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...
(Reuters) -DoorDash forecast third-quarter gross merchandise value above Wall Street expectations after topping estimates on ...
The Philippine economy grew by 5.5 per cent in the second quarter of 2025 from a year earlier, official data showed on ...
Lyft Inc. posted profit in the second quarter that far exceeded Wall Street’s expectations, signaling that the ride-hailing ...
Bumble on Wednesday posted second-quarter revenue above Wall Street estimates, as the dating app begins to bear early fruits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback